As JPM Healthcare Week approaches and investors search for conviction-backed platforms rather than incremental bets, Philadelphia is sending a coordinated signal, Alveus Therapeutics from stealth with a $159.8 million Series A.
Alveus was founded by New Rhein Healthcare Investors, which led the Series A alongside Andera Partners and Omega Funds, with participation from Sanofi, Kurma Partners, and Avego BioScience Capital. The financing positions Alveus among the most highly capitalized obesity-focused startups to launch in recent years.
Built Backward: Designing the Company Before the Asset
Alveus did not follow the typical biotech formation playbook. Rather than starting with a molecule and building outward, New Rhein began with a market thesis: today’s obesity drugs are effective at driving weight loss, but many patients struggle to maintain those gains long term. From that starting point, the firm assembled a leadership team with direct experience shaping the modern obesity market.
Raj Kannan was recruited as chief executive officer, joined by chief scientific officer Jacob Jeppesen, formerly of Novo Nordisk, and chief business officer Brian Bloomquist, who spent nearly two decades at Eli Lilly. Only after the team was in place did Alveus evaluate and license its lead and early-stage programs. The company has not disclosed its licensing partners.
In its launch announcement, Kannan framed the opportunity clearly, pointing to obesity as one of the fastest-growing global healthcare challenges and emphasizing the need for therapies that deliver durable efficacy with improved tolerability and less frequent dosing.
Targeting the Next Phase of a $60B Market
The global obesity drug market is projected to exceed $60 billion by 2030, fueled by widespread adoption of GLP-1 therapies such as Wegovy and Zepbound. Yet adherence challenges, gastrointestinal side effects, and the burden of chronic weekly dosing continue to limit long-term outcomes.
Alveus’ lead candidate, ALV-100, is a fusion protein designed to regulate appetite and glucose while addressing hormonal pathways that can undermine sustained metabolic control. Proceeds from the Series A will support mid-stage clinical development of ALV-100 and advance an earlier selective amylin-based pipeline. Company leadership has indicated that long-term dosing could eventually be measured in months rather than weeks—an approach that, if validated, would represent a meaningful departure from current standards of care.
A Clear Signal of Venture Creation in Philadelphia
Beyond the science, Alveus highlights a notable evolution in how New Rhein is operating. Long known as a healthcare-focused investment firm, New Rhein has increasingly taken on a venture-creation role—assembling leadership teams, defining strategy, and capitalizing companies around clear market needs rather than waiting for external opportunities to emerge.
Nayan Parekh, founder and managing partner of New Rhein and chairman of Alveus, said the firm founded the company to combine a world-class team with cutting-edge science and a long-term focus on patient outcomes in metabolic disease. While New Rhein has previously incubated and closely shaped portfolio companies, Alveus represents one of its clearest examples of this full-stack venture-creation approach.
That strategy is unfolding against a backdrop of renewed confidence in the Philadelphia ecosystem. Century Therapeutics’ recent $135 million private placement—designed to extend its runway into 2029 and support clinical milestones in iPSC-derived cell therapy for Type 1 diabetes—underscores investor willingness to back capital-intensive, long-horizon programs in the region. Meanwhile, the launch of a $50 million Penn-affiliated venture fund signals that local institutions are committing to seed and early-stage formation, not just later-stage participation.
Philadelphia as an Operating Hub, Not a Satellite
Alveus currently employs about 50 people, split roughly evenly between Copenhagen and Philadelphia, with its U.S. team operating from shared space at Two Logan Square. The leadership team also includes chief technical officer Xiao-Ping Dai, adding deep expertise in technical development and manufacturing execution.
The footprint reinforces a broader trend: Philadelphia is increasingly serving as an execution center for globally oriented biotechs, not merely an academic or discovery outpost.
Why It Matters
Taken together, the Alveus launch and Century Therapeutics financing reflect a broader recalibration underway in Greater Philadelphia. Venture creation, late-stage platform confidence, and cross-modal investment—from obesity and metabolic disease to advanced cell therapy—are beginning to reinforce one another. For investors heading into JPM week, the story is less about individual rounds and more about pattern recognition.
Philadelphia is demonstrating that it can originate companies, attract scaled capital, and support complex clinical strategies designed for global competition. As JPM conversations unfold, the question may no longer be whether the region belongs in those rooms—but how often it will help set the agenda.
